Research Paper
OSA treatment history in an upper airway stimulation trial cohort
World Journal of Otorhinolaryngology-Head and Neck Surgery, 2017,03(02) : 79-84. DOI: 10.3760/cma.j.issn.2095-8811.2017.02.103

Analyze the obstructive sleep apnea (OSA) treatment history in a group of participants who enrolled in a hypoglossal nerve stimulation trial.


Moderate-severe OSA patients with difficulty adhering to CPAP presented for enrollment in a multicenter trial. Self-reported history on prior OSA medical therapy was collected at enrollment, including OSA diagnosis date, CPAP start and stop dates, oral appliance trial, and reasons for discontinuation or non-adherence.


The cohort consisted of 929 participants, 83% male, with a mean age (53.9 ± 10.5) years. Ninety percent (n = 835) had complete CPAP information including 47% (n = 435) who discontinued therapy prior to enrollment and 43% (n = 400) who were still attempting CPAP but had inadequate adherence. Abandonment rates were 60% at 1-year, 73% at 3- years, and 86% at 5-years. Oral appliance therapy was attempted by 171 patients for mean (1.8 ± 2.3) years, with 81% abandonment at 1 year, 89% at 3-years, and 94% at 5-years.


In this CPAP-refractory cohort, high rates of CPAP abandonment were reported in the first several years with approximately half of the participants not receiving any treatment despite being diagnosed for >5 years. Close clinical follow-up and consideration of alternative treatment options is indicated in all OSA patients in order to ensure adequate longitudinal care.

Cite as: Soose Ryan J., Padhya Tapan A., Gillespie M. Boyd, et al.  OSA treatment history in an upper airway stimulation trial cohort [J]. World Journal of Otorhinolaryngology-Head and Neck Surgery,2017,03(02): 79-84. DOI: 10.3760/cma.j.issn.2095-8811.2017.02.103
Full Text
Author information
Fund 0  Keyword  0
English Abstract
Visit 0  Comment  0
Related resource
Article | Video

No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission. All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.

No responsibility is assumed by KeAi Communications Co., Ltd. nor Elsevier for any injury and/or damage to persons, property as a matter of product liability, negligence, or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.


Moderate-to-severe obstructive sleep apnea (OSA) has been associated with increased vascular and metabolic health risks as well as patient reported symptoms that include excessive daytime sleepiness, neurocognitive dysfunction, and impaired quality of life.1 Continuous positive airway pressure (CPAP) therapy is the most thoroughly studied therapy with data supporting its safety and effectiveness in accomplishing treatment goals including reduction of cardiovascular risk and improvement in alertness, cognitive function, and quality of life measures.2,3 CPAP therefore remains the standard first-line therapy for moderate to severe OSA.

Expand/close the outline
View figure/chart
Goto top
Bigger Font
Smaller Font
STAR trial
Hypoglossal nerve stimulation
Upper airway stimulation
obstructive sleep apnea
CPAP failure